Skip to main content

Neoadjuvant Nivolumab Plus Ipilimumab Shows Promising Activity in Early-Stage MSI/dMMR Esophagogastric Junction and Gastric Adenocarcinoma

https://dailynews.ascopubs.org/do/10.1200/ADN.22.200801/full/?cmpid=an_ascodn_gi_dailynews_sno_dailynewswebsite_giattendees_011822_021522_twt__

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2023 Esophageal Cancer Education Foundation- by domino